Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Sunshine Biopharma, Inc. (SBFM)

0.5100 +0.2259 (+79.51%)
At close: May 18 at 4:00:00 PM EDT
0.4632 -0.0468 (-9.18%)
Overnight: 12:16:12 AM EDT
Chart Range Bar
Loading chart for SBFM
Chart does not reflect overnight price.
  • Previous Close 0.2841
  • Open 1.8500
  • Bid 0.4385 x 200
  • Ask 0.6685 x 200
  • Day's Range 0.4114 - 2.3200
  • 52 Week Range 0.2810 - 2.4300
  • Volume 414,519,907
  • Avg. Volume 7,217,778
  • Market Cap (intraday) 2.553M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.4400
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 5.60

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

sunshinebiopharma.com

50

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview: SBFM

Trailing total returns as of 5/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SBFM
58.54%
S&P 500 (^GSPC)
8.14%

1-Year Return

SBFM
66.00%
S&P 500 (^GSPC)
24.25%

3-Year Return

SBFM
99.96%
S&P 500 (^GSPC)
76.34%

5-Year Return

SBFM
99.99%
S&P 500 (^GSPC)
79.34%

Earnings Trends: SBFM

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 8.09M
Earnings --

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
2M
4M
6M
8M

Analyst Insights: SBFM

View More

Analyst Price Targets

5.60
5.60 Average
0.5100 Current
5.60 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/8/2025
Analyst Aegis Capital
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 7 -> 7

Statistics: SBFM

View More

Valuation Measures

Annual
As of 5/8/2026
  • Market Cap

    5.18M

  • Enterprise Value

    -3.12M

  • Trailing P/E

    0.20

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.14

  • Price/Book (mrq)

    0.22

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -17.02%

  • Return on Assets (ttm)

    -10.02%

  • Return on Equity (ttm)

    -27.32%

  • Revenue (ttm)

    35.49M

  • Net Income Avi to Common (ttm)

    -6.04M

  • Diluted EPS (ttm)

    -1.4400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.91M

  • Total Debt/Equity (mrq)

    3.46%

  • Levered Free Cash Flow (ttm)

    -4.71M

Compare To: SBFM

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: SBFM

Fair Value

0.5100 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: